Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Definitions and symptoms of the post-COVID syndrome: an updated systematic umbrella review.

European archives of psychiatry and clinical neuroscience·2024
Same author

[79/f-Fall in the bathroom without serious sequelae : Preparation for the medical specialist examination: part 90].

Der Internist·2021
Same author

The prognostic fingerprint of quality of life in older inpatients : Relationship to geriatric syndromes' and resources' profile.

Zeitschrift fur Gerontologie und Geriatrie·2021
Same author

[75/f-apathy, nocturnal restlessness and mild disorientation : Preparation for the medical specialist examination: part 70].

Der Internist·2021
Same author

Does the identification of seniors at risk (ISAR) score effectively select geriatric patients on emergency admission?

Aging clinical and experimental research·2019
Same author

Analysis of cytopenia in geriatric inpatients.

Zeitschrift fur Gerontologie und Geriatrie·2017

Related Experiment Video

Updated: May 25, 2026

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement
10:37

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement

Published on: September 18, 2021

A brief update on dementia prevention.

M C Polidori1, L Pientka

  • 1Department of Geriatrics, Marienhospital Herne, Ruhr University of Bochum, Bochum, Herne, Deutschland. polidori@uni-duesseldorf.de

Zeitschrift Fur Gerontologie Und Geriatrie
|January 27, 2012
PubMed
Summary

Preventing dementia and Alzheimer's disease (AD) requires lifestyle changes, but effective guidelines are challenging due to limited research. Early diagnosis and managing vascular risks are crucial for intervention.

Area of Science:

  • Geriatrics
  • Neurology
  • Public Health

Background:

  • Extensive evidence supports lifestyle interventions for dementia and Alzheimer's disease (AD) prevention.
  • Significant challenges exist in developing effective preventive guidelines.
  • Lack of comparable randomized controlled trials and homogeneous risk management measures hinders progress.

Purpose of the Study:

  • To highlight the need for preventive lifestyle measures against dementia and AD.
  • To identify challenges in guideline development.
  • To emphasize the importance of early diagnosis and risk factor management.

Main Methods:

  • Review of published overview and original articles.
  • Identification of modifiable and non-modifiable risk factors for dementia.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Experiment Videos

Last Updated: May 25, 2026

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement
10:37

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement

Published on: September 18, 2021

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

  • Analysis of challenges in randomized controlled trial design and risk measure homogeneity.

    • Main Results:

    • Non-modifiable risk factors include genes and age.
    • Modifiable risk factors encompass lifestyle habits and vascular health.
    • Deficiencies in high-level evidence and standardized measures impede guideline creation.

    Conclusions:

    • Healthcare professionals should prioritize early cognitive impairment diagnosis.
    • Strategies to control vascular disease and unhealthy lifestyle habits are essential.
    • Interim focus on risk factor management is necessary pending drug therapies and robust evidence.